Literature DB >> 4066773

On the role of 17 alpha-estradiol and 17 beta-estradiol in the proliferation of MCF7 and T47D-A11 human breast tumor cells.

J T Papendorp, R W Schatz, A M Soto, C Sonnenschein.   

Abstract

A comparative study of the proliferative effect of 17 beta-estradiol and 17 alpha-estradiol on human estrogen-sensitive cell lines was performed. When using charcoal-dextran stripped human female sera-supplemented media the administration of the hormones, 17 alpha-estradiol at 3 X 10(-10)M, and 17 beta-estradiol at 3 X 10(-11)M, resulted in a ten-fold increase in cell yield when compared with non-estrogen supplemented controls after cells were grown for periods between 10 to 14 days. No significant metabolization of 17 alpha-estradiol into 17 beta-estradiol occurred as measured by the E2 levels in the supernatants of the cell culture flasks. Increased concentrations of 17 beta-estradiol and 17 alpha-estradiol added to the media bathing C7MCF7-173 cells resulted in a triggering of a partially successful shut-off effect; this phenomenon was not observed with T47D-All cells. These results are compatible with predictions stemming from the indirect and direct negative working hypothesis for the regulation of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4066773     DOI: 10.1002/jcp.1041250331

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population.

Authors:  M Tsuchiya; Y Nakajima; T Waku; H Hiyoshi; T Morishita; R Furumai; Y Hayashi; H Kishimoto; K Kimura; J Yanagisawa
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

2.  Cell cycle synchronization induced by tamoxifen and 17 beta-estradiol on MCF-7 cells using flow cytometry and a monoclonal antibody against bromodeoxyuridine.

Authors:  S Bruno; A Di Vinci; E Geido; W Giaretti
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

3.  The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.

Authors:  Lisa M Privette Vinnedge; Shuk-Mei Ho; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.